Bioprocessing Glossary

Bioprocessing is the use of living cells, biological systems, or enzymes to produce therapeutics such as proteins, antibodies, vaccines, and cell or gene therapies. It includes upstream processing (cell growth) and downstream processing (purification).

Upstream processing involves growing cells in controlled environments (bioreactors) to produce a desired biological product. It includes cell line development, media optimization, and bioreactor scaling.

Downstream processing refers to the purification, separation, and refinement of biologics after cells produce them. Steps include clarification, chromatography, and filtration to achieve clinical-grade purity.

Biomanufacturing is the full end-to-end process of producing biological therapeutics at scale using biotechnology. It includes process development, tech transfer, scale-up, quality control, and commercial manufacturing.

Process intensification uses innovative strategies - such as high-density cell culture, perfusion, or continuous processing - to increase output, reduce footprint, and improve efficiency.

Continuous bioprocessing runs production steps without stopping, allowing cells or materials to flow continuously through systems. It can increase yield, consistency, and efficiency compared to batch processes.

A digital twin is a virtual model of a bioprocess or bioreactor that allows teams to simulate changes, predict outcomes, optimize performance, and troubleshoot without disrupting live production.

CHO (Chinese Hamster Ovary) cells are the most widely used system for producing therapeutic proteins and antibodies. They offer high yield, stability, and regulatory familiarity.

Tech transfer is the process of moving a biomanufacturing process from research or development into pilot or commercial production. It includes documentation, training, validation, and scaling steps.

CMC (Chemistry, Manufacturing, and Controls) requirements refer to the documentation and regulatory processes that ensure biologics are manufactured safely, consistently, and in compliance with regulatory quality standards.

Cell therapy manufacturing involves growing, modifying, and preserving human or engineered cells for therapeutic use. Challenges include scale-up, consistency, automation, and regulatory compliance.

Gene therapy manufacturing produces viral vectors or genetic materials used to deliver therapeutic genes. Key steps include vector production, purification, potency testing, and safety validation.

Analytical development creates the assays and methods used to measure product quality, identity, purity, potency, and safety throughout the bioprocessing workflow.

Scale-up is the process of increasing production volume from lab-scale to pilot and commercial manufacturing while maintaining quality, safety, and performance.

Formulation development ensures that biologics remain stable, active, and safe from manufacturing through storage and delivery (e.g., selecting buffers, excipients, or stabilizers).